HomeTrialNCT06997276
🔬NCT06997276Phase 1RECRUITING

Effect of Hepatic Impairment on the Pharmacokinetics of Mirdametinib

Study Summary

The purposes of this study are to determine: * The pharmacokinetics (the amount of study drug in your blood and how long it takes the body to get rid of it) of the study drug and its metabolites (substances produced as the body breaks down the study drug) in participants with moderate or severe liver function impairment compared to participants with normal liver function (also known as a healthy volunteer). Pharmacokinetics (or PK) is the study of how your body absorbs, breaks down, and removes a study drug. * How well the study drug is tolerated and any side effects that may occur in participants with moderate or severe liver function impairment compared to participants with normal liver function. This study is for research purposes only and is not intended to treat any medical condition.

Interventions / Drugs
View on ClinicalTrials.gov ↗
Study Details
Enrollment32 participants
Primary Completion
Lead SponsorSpringWorks Therapeutics, Inc.
Data Retrieved2026-04-11 04:28:29.597211+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.